{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:42:02Z","timestamp":1788190922362,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.clim.2020.108359","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T11:54:56Z","timestamp":1580903696000},"page":"108359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Cost and impact of early diagnosis in primary immunodeficiency disease: A literature review"],"prefix":"10.1016","volume":"213","author":[{"given":"Kim","family":"Elsink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris M.","family":"van Montfrans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00eblle E.","family":"van Gijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje","family":"Blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Martin","family":"van Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.W.","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert W.J.","family":"Frederix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2020.108359_bb0005","series-title":"Primary Immunodeficiency Diseases","first-page":"1","article-title":"R","author":"Rezaei","year":"2017"},{"issue":"1","key":"10.1016\/j.clim.2020.108359_bb0010","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10875-017-0464-9","article-title":"International Union of Immunological Societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity","volume":"38","author":"Picard","year":"2018","journal-title":"J. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2020.108359_bb0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4065\/84.1.16","article-title":"Incidence and temporal trends of primary immunodeficiency: a population-based cohort study","volume":"84","author":"Joshi","year":"2009","journal-title":"Mayo Clin. Proc."},{"issue":"10","key":"10.1016\/j.clim.2020.108359_bb0020","first-page":"2001","article-title":"Primary immunodeficiencies","volume":"68","author":"Cooper","year":"2011","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.clim.2020.108359_bb0025","first-page":"23","article-title":"Primaire immuundefici\u00ebnties bij kinderen: een update over behandeling en prognose","volume":"1","author":"van Montfrans","year":"2010","journal-title":"Ned. Tijdschr. Allerg. Astma"},{"issue":"5","key":"10.1016\/j.clim.2020.108359_bb0030","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/jcp.2004.016204","article-title":"Primary antibody deficiency and diagnostic delay","volume":"58","author":"Seymour","year":"2005","journal-title":"J. Clin. Pathol."},{"issue":"2","key":"10.1016\/j.clim.2020.108359_bb0035","doi-asserted-by":"crossref","first-page":"S571","DOI":"10.1067\/mai.2003.86","article-title":"Primary immunodeficiency diseases","volume":"111","author":"Bonilla","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"issue":"11","key":"10.1016\/j.clim.2020.108359_bb0040","first-page":"3243","article-title":"Brief report neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn","volume":"117","author":"Brown","year":"2011","journal-title":"Screening."},{"key":"10.1016\/j.clim.2020.108359_bb0045","series-title":"The Year in Human and Medical Genetics: Inborn Errors of Immunity I. Annals of The New York Academy of Sciences","first-page":"122","article-title":"Hematopoietic stem cell transplantation for primary immunnodeficiency diseases","author":"Slatter","year":"2011"},{"issue":"1","key":"10.1016\/j.clim.2020.108359_bb0050","doi-asserted-by":"crossref","DOI":"10.1186\/1476-7961-9-6","article-title":"Relevance of laboratory testing for the diagnosis of primary immunodeficiencies: a review of case-based examples of selected immunodeficiencies","volume":"9","author":"Abraham","year":"2011","journal-title":"Clin. Mol. Allergy"},{"issue":"2","key":"10.1016\/j.clim.2020.108359_bb0055","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1378\/chest.09-2398","article-title":"A CT scan score for the assessment of lung disease in children with common variable immunodeficiency disorders","volume":"138","author":"van de Ven","year":"2010","journal-title":"Chest."},{"issue":"25","key":"10.1016\/j.clim.2020.108359_bb0060","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/blood-2017-05-781849","article-title":"Immune reconstitution and survival of 100 SCID patients post \u2013 hematopoietic cell transplant: a PIDTC natural history study","volume":"130","author":"Heimall","year":"2017","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.clim.2020.108359_bb0065","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clim.2014.10.003","article-title":"Primary immunodeficiencies in the Netherlands: national patient data demonstrate the increased risk of malignancy","volume":"156","author":"Jonkman-Berk","year":"2015","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2020.108359_bb0070","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.alit.2017.06.003","article-title":"Flow cytometry-based diagnosis of primary immunodeficiency diseases","volume":"67","author":"Kanegane","year":"2018","journal-title":"Allergol. Int."},{"key":"10.1016\/j.clim.2020.108359_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ."},{"issue":"7","key":"10.1016\/j.clim.2020.108359_bb0080","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2217\/imt.14.54","article-title":"Immunoglobulin replacement therapy for primary immunodeficiencies","volume":"6","author":"Peter","year":"2014","journal-title":"Immunotherapy."},{"key":"10.1016\/j.clim.2020.108359_bb0085","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM197703312961304","article-title":"Foundations of cost-effectiveness analysis for health and medical practices","author":"Weinstein","year":"1977","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.clim.2020.108359_bb0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0277-9536(94)90162-7","article-title":"Cost utility analysis: what should be measured?","volume":"39","author":"Richardson","year":"1994","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.clim.2020.108359_bb0095","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"1997"},{"issue":"1","key":"10.1016\/j.clim.2020.108359_bb0100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s10198-004-0250-5","article-title":"Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance","volume":"6","author":"H\u00f6gy","year":"2005","journal-title":"Eur. J. Health Econ."},{"issue":"3","key":"10.1016\/j.clim.2020.108359_bb0105","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2249.2007.03520.x","article-title":"A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency","volume":"150","author":"Kallenberg","year":"2007","journal-title":"Clin. Exp. Immunol."},{"issue":"9","key":"10.1016\/j.clim.2020.108359_bb0110","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.intimp.2011.04.021","article-title":"Kiovig for primary immunodeficiency: reduced infusion and decreased costs per infusion","volume":"11","author":"Connolly","year":"2011","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.clim.2020.108359_bb0115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-3148.2012.01201.x","article-title":"Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency","volume":"23","author":"Martin","year":"2013","journal-title":"Transfus. Med."},{"issue":"11","key":"10.1016\/j.clim.2020.108359_bb0120","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.clinthera.2014.08.007","article-title":"Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency","volume":"36","author":"Igarashi","year":"2014","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.clim.2020.108359_bb0125","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.anai.2017.11.002","article-title":"Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: a prospective economic analysis","volume":"120","author":"Fu","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"2","key":"10.1016\/j.clim.2020.108359_bb0130","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2249.2009.04079.x","article-title":"Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies","volume":"160","author":"Beaut\u00e9","year":"2010","journal-title":"Clin. Exp. Immunol."},{"issue":"4","key":"10.1016\/j.clim.2020.108359_bb0135","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1524-4733.2005.00040.x","article-title":"Cost savings from intravenous immunoglobulin manufactured from chromotography\/caprylate (IGIV-C) in persons with primary humoral immunodeficiency disorder","volume":"8","author":"Mahadevia","year":"2005","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.clim.2020.108359_bb0140","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s10875-016-0288-z","article-title":"Switching patients to home-based subcutaneous immunoglobulin: an economic evaluation of an interprofessional drug therapy management program","volume":"36","author":"Perraudin","year":"2016","journal-title":"J. Clin. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2020.108359_bb0145","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jaip.2014.05.013","article-title":"Fiscal implications of newborn screening in the diagnosis of severe combined immunodeficiency","volume":"2","author":"Kubiak","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.clim.2020.108359_bb0150","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.jaci.2016.10.043","article-title":"Costs associated with treatment of severe combined immunodeficiency\u2014rationale for newborn screening in Sweden","volume":"139","author":"Gardulf","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2020.108359_bb0155","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.jaci.2015.02.004","article-title":"Systematic neonatal screening for severe combined immunodeficiency and severe T-cell lymphopenia: analysis of cost-effectiveness based on French real field data","volume":"135","author":"Cl\u00e9ment","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"March","key":"10.1016\/j.clim.2020.108359_bb0160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clim.2019.03.012","article-title":"Clinical and economic aspects of newborn screening for severe combined immunodeficiency: DEPISTREC study results","volume":"202","author":"Thomas","year":"2019","journal-title":"Clin. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2020.108359_bb0165","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ymgme.2011.07.007","article-title":"A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID)","volume":"104","author":"Chan","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.clim.2020.108359_bb0170","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jpeds.2016.01.029","article-title":"Cost-effectiveness\/cost-benefit analysis of newborn screening for severe combined immune deficiency in Washington State","volume":"172","author":"Ding","year":"2016","journal-title":"J. Pediatr."},{"issue":"5","key":"10.1016\/j.clim.2020.108359_bb0175","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00431-019-03346-3","article-title":"Cost-effectiveness of newborn screening for severe combined immunodeficiency","volume":"178","author":"Van Der Ploeg","year":"2019","journal-title":"Eur. J. Pediatr."},{"issue":"5","key":"10.1016\/j.clim.2020.108359_bb0180","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jpeds.2005.06.001","article-title":"Potential costs and benefits of newborn screening for severe combined immunodeficiency","volume":"147","author":"McGhee","year":"2005","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.clim.2020.108359_bb0185","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1007\/s12026-016-8784-z","article-title":"Primary immunodeficiencies worldwide: an updated overview from the Jeffrey Modell Centers Global Network","volume":"64","author":"Modell","year":"2016","journal-title":"Immunol. Res."},{"issue":"1","key":"10.1016\/j.clim.2020.108359_bb0190","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12026-011-8241-y","article-title":"Global study of primary immunodeficiency diseases (PI)-diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation","volume":"51","author":"Modell","year":"2011","journal-title":"Immunol. Res."},{"issue":"3","key":"10.1016\/j.clim.2020.108359_bb0195","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s12026-017-8907-1","article-title":"Modeling strategy to identify patients with primary immunodeficiency utilizing risk management and outcome measurement","volume":"65","author":"Modell","year":"2017","journal-title":"Immunol. Res."},{"issue":"5","key":"10.1016\/j.clim.2020.108359_bb0200","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1586\/1744666X.2015.1029457","article-title":"Economic burden of common variable immunodeficiency: annual cost of disease","volume":"11","author":"Sadeghi","year":"2015","journal-title":"Expert. Rev. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2020.108359_bb0205","first-page":"342","article-title":"Costs of hospital admission on primary immunodeficiency diseases","volume":"46","author":"Gholami","year":"2017","journal-title":"Iran. J. Public Health"},{"issue":"4","key":"10.1016\/j.clim.2020.108359_bb0210","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10875-014-0029-0","article-title":"The case for mandatory newborn screening for severe combined immunodeficiency (SCID)","volume":"34","author":"Gaspar","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2020.108359_bb0215","doi-asserted-by":"crossref","DOI":"10.1007\/s10875-013-9952-8","article-title":"Severe combined immunodeficiency (SCID) in Canadian children: a national surveillance study","author":"Rozmus","year":"2013","journal-title":"J. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2020.108359_bb0220","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10875-008-9250-z","article-title":"Long-term neurocognitive function of pediatric patients with severe combined immune deficiency (SCID): pre- and post-hematopoietic stem cell transplant (HSCT)","volume":"29","author":"Lin","year":"2009","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2020.108359_bb0225","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9647253","article-title":"The utility of next-generation sequencing for primary immunodeficiency disorders: experience from a clinical diagnostic laboratory","author":"Bisgin","year":"2018","journal-title":"Biomed. Res. Int."},{"issue":"2","key":"10.1016\/j.clim.2020.108359_bb0230","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jaci.2013.08.032","article-title":"Targeted next-generation sequencing: a novel diagnostic tool for primary immunodeficiencies","volume":"133","author":"Nijman","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2020.108359_bb0235","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/cge.13163","article-title":"Clinical efficacy of a next-generation sequencing gene panel for primary immunodeficiency diagnostics","volume":"93","author":"Rae","year":"2018","journal-title":"Clin. Genet."},{"key":"10.1016\/j.clim.2020.108359_bb0240","doi-asserted-by":"crossref","DOI":"10.1007\/s10875-019-00656-x","article-title":"Diagnostic yield of next generation sequencing in genetically undiagnosed patients with primary Immunodeficiencies: a systematic review","author":"Yska","year":"2019","journal-title":"J. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2020.108359_bb0245","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.paed.2016.11.001","article-title":"Advances in primary immunodeficiencies","volume":"27","author":"Battersby","year":"2017","journal-title":"Paediatr. Child Health (Oxford)"},{"key":"10.1016\/j.clim.2020.108359_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2010.06.015","article-title":"Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better?","author":"Gennery","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2020.108359_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2011.03.028","article-title":"Chronic granulomatous disease: overview and hematopoietic stem cell transplantation","author":"Kang","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3 (Supplement)","key":"10.1016\/j.clim.2020.108359_bb0260","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1016\/j.bbmt.2015.11.804","article-title":"Allogeneic hematopoietic stem cell transplantation (HSCT) for high risk chronic granulomatous disease (CGD) patients","volume":"22","author":"Kang","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.clim.2020.108359_bb0265","doi-asserted-by":"crossref","DOI":"10.1007\/s10875-011-9511-0","article-title":"Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study","author":"Quinti","year":"2011","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2020.108359_bb0270","author":"World Bank Group. Data, Country Classification"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166161930186X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166161930186X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:00:15Z","timestamp":1761494415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152166161930186X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":54,"alternative-id":["S152166161930186X"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2020.108359","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost and impact of early diagnosis in primary immunodeficiency disease: A literature review","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2020.108359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108359"}}